Porphyrin derivatives, and in particular Verteporfin (VP), a photosensitizer initially designed for cancer therapy, have been identified as inhibitors of YAP-TEAD interaction and transcriptional activity. We herein report the efficient convergent synthesis of the dipyrrin western half-part of protoporphyrin IX dimethyl ester (PPIX-DME) where the sensitive vinyl group was created at the final stage by a dehydroiodation reaction. Two other dipyrrin derivatives were synthesized including dipyrrin 19 containing two vinyl groups. We found that VP and dipyrrin 19 showed a significant inhibitory effect on TEAD transcriptional activity in MDA-MB-231 cells whereas other compounds did not show significant changes. In addition, we observed a marked decrease in both YAP and TAZ levels following VP treatment whereas dipyrrin 19 treatment primarily reduced the level of YAP and the receptor kinase Axl, a downstream target of YAP. Altogether, our data suggests that in function of their chemical structure, porphyrin-and dipyrrin-related derivatives can directly target YAP and/or TAZ proteins and inhibits TEAD transcriptional activity.
Introduction
YAP(TAZ), the downstream effectors of the Hippo pathway, interact with TEAD to regulate stem cell proliferation, tissue growth and organ size [4] . Oncogenic YAP/TAZ are overexpressed in many cancers [5] [6] [7] [8] causing overgrowth phenotypes and metastasis. Liu-Chittenden and colleagues [9] were the first to demonstrate to feasibility to disrupt YAP/TEAD complex as a pertinent therapeutic strategy in cancer therapy and identified three members of the porphyrin family, namely VP, protoporphyrin IX (PPIX) and hematoporphyrin (HP), as inhibitors of YAP/TEAD-dependent transcription. VP was found to be the most effective compound to inhibit the complex between YAP and TEAD2 and was used VP for in vivo validation. Indeed, VP treatment efficiently suppressed liver overgrowth induced by YAP overexpression in mice models. Verteporfin, is a photosensitizer initially designed for cancer therapy, which presents high cytotoxicity for tumor cells only under light stimulation [1] . Rapidly VP was repositioned in the field of ophthalmology and photodynamic therapy for the treatment of age-related macular degeneration [2] (VP was FDA-approved in 2000 and marketed by Novartis under the trade name: visudyne ® ).
VP was recently reported to exert different biological properties without light activation [3 and references cited therein]. However, the use of VP as an inhibitor of YAP-induced overgrowth presents several drawbacks: (i) it is a photosensitizer and therefore is highly phototoxic; (ii) it has been identified as an inhibitor of autophagy via a low-level production of singlet oxygen [10] ; (iii) it induces the oligomerization of up to 250 proteins including 80 mitochondrial proteins [11] ; (iv) it has also been reported that VP up-regulates 14-3-3 (a protein responsible for the cytoplasmic retention of YAP) [12] . So, several questions therefore arise on how VP interacts with YAP. In this paper, we first focused our attention on the structural features that confer to VP its ability to control the YAP/TEAD interaction and decrease the induction of the main target genes. For this purpose, we first compared the biological properties of VP, PPIX and its dimethyl ester ( Figure 1 ) in MDA-MB-231 breast cancer cell line. In a second round, we synthesized the hexasubstituted dipyrrin 1 corresponding to the western part of PPIX dimethyl ester (PPIX-DME). We report herein the first convergent synthesis of this dipyrrin derivative starting from the known 2-formylpyrrole 2 (Scheme 1) [13] . Additionally, we synthesized two other symmetric hexasubstituted dipyrrins 18 and 19 and report their cellular activities on the YAP(TAZ)/TEAD complexes. Chemistry of dipyrrins [14] is directly connected to the synthesis of porphyrins and the access to dipyrrinato complexes possessing remarkable optical properties, however nothing is known about the biological properties of this class of molecules. The biological evaluation has been made in two distinct steps: firstly, as a reference, we measured the effect of the inhibition of expression YAP and/or TAZ by siRNA in MDA-MB-231 cells on the expression of some relevant target genes (Cyr61, CTGF and AXL). In a second time, we measured the biological effect of VP and related protoporphyrins and dipyrrins on by using two different methods: 1-measurement of TEAD transcriptional activity using 8xGTIIC-luciferase reporter assay [15] , 2evaluation of the protein levels of Cyr61, CTGF and AXL.
Results and Discussion
Chemistry Our first strategy to obtain the dipyrrin 1 (Scheme 1) was inspired from the total synthesis of hematoporphyrin published by Martin et al. [16] . Scheme 1. (a) HBr 33% in AcOH (8 eq.), MeOH, rt, 1 h, 89%; (b) CeCl3.7H2O (1 eq.), NaBH4 (2 eq.), dioxane/propan-2-ol, 100 °C, 20 h, 75%.
The condensation of the two pyrrolo units 2 [17] and 3 [18] using HBr in acetic acid gave the dipyrrin 4 with high yield (89%) but the reduction of the acetyl group in presence of NaBH4 [15] alone or with CeCl3 [19] yielded the dipyrromethane 5' instead of the expected alcohol 5.
In a second strategy (Scheme 2), we planned to obtain the target compound 1 through the similar condensation of the pyrrolo units 2 and 8. Firstly the vinylpyrrole 8 was obtained via the Stille vinylation [20] of the iodopyrrole 6. Unfortunately, vinylpyrrole 8 was found to be unstable under the acidic conditions required for the dipyrrin synthesis.
The third strategy (Scheme 3) consisted in the ultimate Stille vinylation of the iododipyrrin 10 which could be issued from the condensation of the formylpyrrole 2 and the iodopyrrole 9 [21, 22] . Unfortunately, the condensation of the two pyrrolo units 2 and 7 yielded the unexpected deiododipyrrin 11. Scheme 2. (a) Vinyltributyltin (2 eq.), Pd(PPh3)2Cl2 (0.05 eq.), toluene, 110 °C, 2 h, 48%; (b) LiOH (8 eq.), EtOH/H2O, 90 °C, 8 h, 32%; (c) HBr 33% in AcOH (8 eq.), MeOH, rt, 1h. Scheme 3. (a) HBr 33% in AcOH (8 eq.), MeOH, rt, 1 h, 75%; (b) Vinyltributyltin (2 eq.), Pd(PPh3)2Cl2 (0.05 eq.), toluene, 110 °C, 2 h.
Our fourth strategy (Scheme 4) was based on the condensation of the formylpyrrole 2 and the iodoethylpyrrole 13 (synthesized from the known hydroxyethylpyrrole 12 [23] ). Base-induced dehydroiodation of the yielded iodoethyldipyrrin 14 gave successfully the target dipyrrin 1 with a moderate yield (47%). Symmetric tetramethyldi(3-methoxy-3-oxopropyl)dipyrrin 18 and di(2-iodoethyl)tetramethyldipyrrin 17 were also synthesized using the same strategy than for the synthesis of 14 (Scheme 5). 18 was obtained with the same yield as recently reported by Lund and Thompson, who synthesized symmetric dipyrrin hydrobromides from 2-formylpyrroles [24] . The double dehydroiodation of di(2-iodoethyl)tetramethyldipyrrin 17 using DBU gave tetramethyldivinyldipyrrin 19 with a modest 36% yield. (Scheme 5). Scheme 4. (a) PPh3 (2 eq.), Imidazole (2 eq.), I2 (2 eq.), DCM, rt, 20 h, 83%; (b) i) TFA (44 eq.), rt, 30min ii) HBr 33% in AcOH (8 eq.), MeOH, rt, 1 h, 63%; (c) DBU (2.5 eq.), DCM, rt, 20 h, 47%. Scheme 5. (a) HBr 33% in AcOH (8 eq.), MeOH, rt, 1 h, 65% for 17 and 68% for 18; (b) DBU (4 eq.), DCM, rt, 20 h, 36%.
Biology YAP and TAZ are transcriptional coactivators that function as effectors of the Hippo pathway. To maintain Hippo pathway homeostasis, TAZ accumulation can be negatively regulated by YAP abundance [25] . More recently, Moroishi et al. [26] reported a reciprocal negative regulation between these two coactivators in MCF10A cells, through TEAD-dependent transcription. Submitted to oxidative stress, differences were found between YAP and TAZ. TAZ was less sensitive to oxidative stress than YAP [27] . For these reasons, we focused our attention on the effects of VP, PPIX and dipyrrins on the two Hippo pathway effectors (YAP and TAZ) and on the YAP(TAZ)/TEAD gene targets (Axl, Cyr61 and CTGF). Depending on the cell lines, the Hippo pathway effectors can be differently expressed. This has been clearly shown on different colon cancer cell lines by some of us [15] that HT-29 cells expressed mainly YAP whereas HCT-116 or RKO cells expressed both YAP and TAZ. Moreover, the relative TEAD activity is also cell line-dependent. We selected MDA-MB-231 breast cancer cell line because it similarly expressed YAP and TAZ co-activators, presented a high TEAD transcriptional activity and yielded a high expression of gene targets (Axl, Cyr61 and CTGF).
We first analyzed the expression of mRNA (by RT-qPCR) and proteins (Western Blot) of YAP, TAZ, AXL, Cyr61 and CTGF in the presence of siYAP, siTAZ or both (Si Y-T). Knockdown of either YAP or TAZ decreased the expression of gene targets ( Figure 2 ) but did not show any selectivity of one co-activator. Dual YAP/TAZ knockdown significantly decreased the protein levels of Cyr61, CTGF and Axl. As previously reported [10] , VP is a photoactivable molecule and exposure to light must always be stringently avoided during cell treatment. However, even in the absence of light, we observed a decrease in YAP and TAZ levels in western blots. While the RNA expression of YAP is not affected (Figure 2A ), its protein production decreases by 74%. This already reported proteotoxicity [11] was also observed TAZ ( Figure 2B ) even if TAZ could be considered to be less sensitive to oxidative stress conditions [27] . The reduction of YAP expression was previously reported in hepatocellular carcinoma cells treated by a 1,2dithiole-3-thione derivative [28] , known to generate in vitro superoxide anion [29] and hydrogen peroxide [30] . VP (10 µM) efficiently decreased the mRNA expression of the downstream gene targets ( Figure 3A) . At the protein levels, AXL, and CTGF appeared mostly affected ( Figure 3B ). CTGF was already found to be more sensitive than Cyr61 in ovarian cancer cells treated by VP [31] . Inversely, VP affects more efficiently Cyr61 than CTGF in retinoblastoma cells [32] . It may be suggested that VP could also affect Axl, and CTGF levels through its proteotoxic properties. Using the TEAD luciferase assay, we measured the ability of VP and related compounds to inhibit the TEAD activity ( Figure 3 ). We found that VP at a 10 µM concentration inhibited this activity by 50%. Tested protoporphyrins and dipyrrins did not show significant effect except dipyrrin 19.
Conversely to the results obtained in HEK293 cells [9] , we did not observe a significant decrease of the TEAD luciferase activity following PPIX (or PPIX-DME) treatment. We then analyzed the effect of PPIX, PPIX-DME and dipyrrin derivatives on the expression of YAP, TAZ and their target genes. Conversely to VP, PPIX, PPIX-DME did not induce a dramatic decrease in YAP and TAZ ( Figure 4 ). This may be related to the expected weaker proteotoxicity of both compounds, which possess a significantly lowest singlet oxygen quantum yield than VP [3] . Dipyrrin 1, the western part of protoporphyrin IX dimethyl ester (PPIX-DME) did not show any significant changes. But interestingly, symmetric dipyrrin 19 containing two vinyl groups significantly decreased the level of YAP whereas TAZ level remained at a similar level. This result is well connected to the fact that dipyrrin 19 is the only dipyrrin derivative able to induce a decrease in TEAD transcriptional activity in the TEAD luciferase assay. This derivative also resulted in a decrease in AXL level. 
Conclusion
We successfully synthesized the dipyrrin western part of protoporphyrin IX, dipyrrin 1, from the known tert-butyl 4-(2hydroxyethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate.
The sensitive vinyl group was created at the final stage by a dehydroiodation reaction. We submitted dipyrrin 1 to Diels-Alder reaction conditions but failed to obtain the western part of VP due to the unstability of 1 to prolonged heat at toluene boiling point. This dipyrrin 1 could be useful to study other biological properties. Using the same strategy,the divinyl-dipyrrin 19 was synthesized. Independently to its mechanism of action, it has been wellestablished in several animal models that VP administration allows to control efficiently the organ growth via the Hippo pathway. VP has been firstly reported as a YAP/TEAD complex inhibitor whereas its ability to oligomerize several cellular proteins could correspond to a low protein selectivity [11] . We observed that VP significantly inhibits the TEAD luciferase activity in agreement to previously reported data [9] . However, we also observed that VP decreases the expression of YAP and TAZ, and such effect must result in a decrease in YAP/TEAD cotranscriptional activity. It has been reported that VP can induce the formation of high molecular weight oligomers through a crosslinking of proteins potentiated by oxidative stress [10] . The decrease in YAP and TAZ here observed after VP treatment might result from oligomerization of these proteins. In addition, we identified here a compound, dipyrrin 19, able to decrease YAP level and TEAD transcriptional activity. It may be suggested that such effect of dipyrrin 19 can be due the addition of two vinyl groups to the dipyrrin skeleton resulting in proteotoxicity. Altogether, these data suggest that in function of their chemical structure, porphyrin-and dipyrrin-related derivatives can directly target YAP and/or TAZ proteins and inhibits TEAD transcriptional activity. VP, which is mainly localized in mitochondria, might also affected the YAP and TAZ expression via the mitochondrial fusion/Hippo pathway cross-talking [33] . This link between Hippo pathway and mitochondria fusion could be of significance to cancer biology [34] .
Experimental Section
Biology Human breast cancer cell line MDA-MB-231 cell line was purchased from the American Type Culture Collection and cultivated in DMEM media containing 10% of heat inactivated FBS, L-glutamine and penicillin/streptomycin. Western blotting Total extracts of cells were obtained with a RIPA based buffer containing protease and phosphatase inhibitors (Roche). Western blot were carried out using 20 μg of protein lysates with the NuPage Electrophoresis and Iblot transfer systems (Life Technologies). β-Actin was used as loading control for total extracts, TEAD transcriptional activity Cells at 50% confluence were transfected with the TEAD luciferase reporter plasmid 8XGTIIC-Luciferase (Addgene reference 34615) vs a control luciferase plasmid. After 48 hours post transfection, cells are lysed in Reporter Lysis Buffer (Promega) and luciferase activity was measured on the Mithras LB940 plate reader and normalized to protein concentration. mRNA expression mRNAs were extracted from cultured cells or human tumors with the NucleoSpin kit (Macherey-Nagel). Retrotranscription was done on 1 μg of mRNA accordingly to the Advantage RT-for-PCR Kit protocol (Clontech). PCR was performed using SsoFastTM Evagreen Supermix kit following the manufacturer's protocol using the CFX96 real time PCR system (Bio-Rad). To monitor any change in mRNA expression, we used the ΔΔCt method between one condition and a control condition after normalization with the housekeeper gene RPLP0. Each sample was done in triplicate.
Chemistry
Chemicals and solvents were purchased from various suppliers (Sigma-Aldrich, Alfa Aesar, Fisher, VWR) and used without purification. The reaction monitoring was performed by thin layer chromatography (TLC) on Macherey-Nagel Alugram® Sil 60/UV254 (thickness 0.2 mm). TLC were revealed by UV (λ = 254 nm) and/or the appropriate stain. Purification of the compounds was carried out by column chromatography (flash or manual). Manual chromatography was performed using Macherey-Nagel silica gel (0.04-0.063 mm of particule size). Flash chromatography was performed on a Reveleris® Flash Chromatography System using Macherey-Nagel Chromabond flash RS columns. NMR spectra were recorded on a Bruker DRX 300 spectrometer (operating at 300 MHz for 1 H and 75 MHz for 13 The UV-vis spectra were recorded using a NanoDrop spectrometer (ThermoFisherScientific). Characteristic peaks are given in nm and classified according to their relative intensity (s strong, m medium, w weak).
(Z)-4-Acetyl-2-((4-(3-methoxy-3-oxopropyl)-3,5-dimethyl-1H-pyrrol-2yl)methylene)-3,5-dimethyl-2H-pyrrolium bromide (4)
A solution of 33% HBr in AcOH (2.7 eq., 497 mg, 0.3 mL, 2.9 mmol) was added dropwise to a solution of methyl 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)propanoate [17] (1 eq., 228 mg, 1.1 mmol) and 3-acetyl-2,4dimethylpyrrole [18] (1 eq., 150 mg, 1.1 mmol) in MeOH (3 mL) at room temperature under nitrogen atmosphere. The mixture was stirred at room temperature for 4 h and the product was collected by filtration. The residue was used without further purification in the next step. The title compound (400 mg, 0.97 mmol, 89%) was obtained as an orange solid. 1 
Methyl 3-(5-((4-acetyl-3,5-dimethyl-1H-pyrrol-2-yl)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)propanoate (5')
Dipyrrin 4 (1 eq., 0.19 g, 0.46 mmol) was dissolved in a mixture of DCM (28 mL) and MeOH (7 mL). Sodium borohydride (5.0 eq., 88 mg, 2.3 mmol) was added in one portion and the mixture was stirred at room temperature for 2 h. Then the solution was washed with saturated aqueous bicarbonate solution and brine, dried over sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (DCM/MeOH, 95:5 (v/v), NH3g sat).The title compound (115 mg, 0.35 mmol, 75%) was obtained as an orange solid. 1 
Ethyl 4-iodo-3,5-dimethyl-1H-pyrrole-2-carboxylate (6)
To a solution of N-chlorosuccinimide (1.2 eq., 0.96 g, 7.2 mmol) in DMF (20 mL) was added NaI (1.2 eq., 1.08 g, 7.2 mmol) in small portions. The resulting brown solution was stirred at room temperature for 1 h before the slow addition at 0 °C of ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 1 g, 6.0 mmol) in DMF (20 mL). The reaction was stirred at room temperature for 1 h. Aqueous 10% sodium thiosulfate solution (20 mL) was added and the mixture was stirred for 1 h. The solid was collected by filtration. The residue was used without further purification in the next step. The title compound (1.61 g, 5.5 mmol, 92%) was obtained as a white solid. 
Ethyl 3,5-dimethyl-4-vinyl-1H-pyrrole-2-carboxylate (7)
A mixture of ethyl 4-iodo-3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 1.00 g, 3.4 mmol) , vinyltributyltin (2 eq., 2.16 g, 2.0 mL, 6.8 mmol) and bis(triphenylphosphine)palladium(II) dichloride (5 %, 0.12 g, 0.17 mmol) in toluene (50 mL) was refluxed for 2 h under a nitrogen atmosphere. During the course of the reaction, the color changed from yellow to black as Pd° was formed. The reaction was cooled to room temperature and DCM (50 mL) was added. The resulting solution was washed with satured aqueous NaCl (50 mL) and water (50 mL). The organic phase was separated, dried over Na2SO4 and concentrated under vacuum. The residue was purified by flash chromatography (DCM/MeOH, 95:5 (v/v)). The title compound (317 mg, 1.6 mmol, 48%) was obtained as a dark brown solid. 
3,5-Dimethyl-4-vinyl-1H-pyrrole-2-carboxylic acid (8)
Ethyl 4-ethenyl-3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 158 mg, 0.82 mmol) and LiOH (8 eq., 156 mg, 6.5 mmol) were dissolved in EtOH (2 mL) and H2O (2 mL) . The solution was heated at 90 °C for 1 h. The solvent was evaporated under vacuum. The residue was taken up in EtOAc (5 mL) and water (5 mL). The aqueous layer was acidified until pH 5.0 with H3BO3 (pH 5.1) or a few drops of concentrate H2SO4 before being extracted with EtOAc. Organics layers were dried over Na2SO4 and concentrated under vacuum. The residue was used without further purification in the next step. The title compound (43 mg, 0.3 mmol, 32%) was obtained as a dark brown solid. 1 
4-iodo-3,5-dimethyl-1H-pyrrole-2-carboxylic acid (9)
Ethyl 4-iodo-3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 500 mg, 1.7 mmol) and LiOH (8 eq., 326 mg, 13.6 mmol) were dissolved in EtOH (5 mL) and H2O (5 mL). The solution was heated at 90 °C for 1 h. The solvent was evaporated under vacuum. The residue was taken up in EtOAc (50 mL) and water (50 mL). The aqueous layer was acidified to pH 5.0 with H3BO3 (pH 5.1) or few drops of concentrate H2SO4 before being extracted with EtOAc. Organics layers were dried over sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (DCM/MeOH, 95:5 (v/v)). The title compound (399 mg, 1.5 mmol, 88%) was obtained as a dark pink solid. 1 
(Z)-3-((4-(3-methoxy-3-oxopropyl)-3,5-dimethyl-1H-pyrrol-2yl)methylene)-2,4-dimethyl-3H-pyrrol-1-ium bromide (11)
A solution of 48% HBr in water (2.7 eq., 0.18 mL, 1.6 mmol) was added dropwise to a solution of pyrrole 2 (1 eq., 0.12 g, 0.6 mmol) and pyrrole 9 (1 eq., 0.16 g, 0.6 mmol) in methanol (1.5 mL).The mixture was stirred for 1 h at room temperature and concentrated under vacuum. The residue was purified by flash chromatography (DCM/MeOH, 95:5 (v/v)). The title compound (65 mg, 0.2 mmol, 30%) was obtained as a dark brown solid. 1 
Tert-butyl 4-(2-iodoethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (13)
Tert-butyl 4-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 100 mg, 0.42 mmol) , imidazole (2 eq., 56.9 mg, 0.84 mmol) and triphenylphosphine (2 eq., 219 mg, 0.84 mmol) were dissolved in DCM (5 mL) under a nitrogen atmosphere at room temperature. After complete dissolution, iodine (2 eq., 212 mg, 0.84 mmol) was added portionwise at 0 °C. The mixture was stirred overnight at room temperature. The reaction was quenched with aqueous 10% Na2S2O3 solution (10 mL). The aqueous layer was extracted with DCM (3 x 10 mL), dried over Na2SO4 and concentrated under vacuum. The residue was purified by flash chromatography (Cyclohexane/EtOAc, 7:3 (v/v)). The title compound (138 mg, 0.4 mmol, 95%) was obtained as a white solid. 1 (14) TFA (44.4 eq., 1.15 mL, 25.5 mmol) was added dropwise to a solution of tert-butyl 4-(2-iodoethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 200 mg, 0.57 mmol) at room temperature under a nitrogen atmosphere. The solution was stirred for 30 min. Then, a solution of methyl 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)propanoate (1 eq., 119 mg, 0.57 mmol) in MeOH (2.3 mL) was added dropwise, followed by 33% HBr solution in AcOH (8.99 eq., 1263 mg, 0.86 mL, 5.1 mmol). The mixture was stirred at room temperature for 1 h and the product was collected by filtration. The residue was used without further purification in the next step. The title compound (200 mg, 0.38 mmol, 67%) was obtained as an orange solid. 1 (16) TFA (9 eq., 0.59 mL, 7.7 mmol) was added dropwise to a solution of tertbutyl 4-(2-iodoethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 0.3 g, 0.9 mmol) in DCM (4 mL) at 0 °C under a nitrogen atmosphere. Trimethyl orthoformate (5 eq., 0.47 mL, 4.3 mmol) was added dropwise and the reaction was stirred under N2 for 20 min at 0 °C. The solution was warmed to room temperature and stirred for 30 min. The mixture was neutralized carefully with aqueous 10% NaHCO3 solution and extracted with DCM (3 x 20 mL). The combined organic layers dried over Na2SO4 and concentrated under vacuum. The residue was purified by flash column chromatography with Cyclohexane/EtOAc (8:2). The title compound (150 mg, 0.5 mmol, 63 %) was obtained as light brown solid. 
(Z)-4-(2-Iodoethyl)-2-((4-(2-iodoethyl)-3,5-dimethyl-1H-pyrrol-2yl)methylene)-3,5-dimethyl-2H-pyrrolium bromide (17)
TFA (27 eq., 1.1 mL, 14.5 mmol) was added dropwise to a solution of tertbutyl 4-(2-iodoethyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (1 eq., 0.19 g, 0.5 mmol) at room temperature under a nitrogen atmosphere. The solution was stirred for 30 min. Then a solution of 4-(2-iodoethyl)-3,5-dimethyl-1Hpyrrole-2-carbaldehyde (1 eq., 0.15 g, 0.5 mmol) in MeOH (2 mL) was added dropwise, followed by 33% HBr in AcOH (8.6 eq., 0.81 mL, 4.6 mmol). The mixture was stirred at room temperature for 1 h and the product was collected by filtration. The residue was used without further purification in the next step.
The title compound (0.2 g, 0.3 mmol, 65%) was obtained as a dark red solid. 1 
)-3,5-dimethyl-1H-pyrrol-2yl]methylidene}-3,5-dimethyl-2H-pyrrol-1-ium bromide (1 eq., 170 mg, 0.3 mmol) was dissolved in dry DCM (3 mL) under a nitrogen atmosphere. DBU (4 eq., 0.172 mL, 1.2 mmol) was added dropwise to the solution at room temperature and the mixture was heated at 50 °C. After complete reaction, the solvent was evaporated under vacuum and the solid residue was purified by flash column chromatography with DCM/MeOH (95:5). The title compound (26 mg, 0.1 mmol, 36%) was obtained as a brown solid. UV-vis (Acetonitrile) max (nm) 506 (s), 366 (s), 292 (s), 230 (s). 1 TFA (44 eq., 1.56 mL, 21.1 mmol) was added dropwise to a solution of 4-(3-methoxy-3-oxopropyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid (1 eq., 110 mg, 0.50 mmol) at room temperature under a nitrogen atmosphere. The solution was stirred for 30 min. Then, a solution of methyl 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)propanoate (1 eq., 100 mg, 0.50 mmol) in MeOH (2.0 mL) was added dropwise, followed by 33% HBr solution in AcOH (8.6 eq., 1.13 g, 0.81 mL, 4.6 mmol). The mixture was stirred at room temperature for 1 h and the product was collected by filtration. The residue was used without further purification in the next step. The title compound (192 mg, 0.40 mmol, 63%) was obtained as a brown solid. UV-vis (Acetonitrile) max (nm) 480 (s), 392 (w), 226 (m). 
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